Sagimet Biosciences Stock Discussion

$Sagimet Biosciences (SGMT.US)$ Nice to see a bit of a recovery🤫

$Sagimet Biosciences (SGMT.US)$
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...

$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins ago
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash

$Sagimet Biosciences (SGMT.US)$ Sagimet Biosciences Presented Data From FASCINATE-2 Phase 2B Trial Of Denifanstat Versus Placebo In Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis Patients At The European Association For The Study Of The Liver Congress Benzinga · 4 mins  Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for ac...

Here are the levels to watch on this low volume drop.
Larger Image: tradingview.com...
$Sagimet Biosciences (SGMT.US)$

$Sagimet Biosciences (SGMT.US)$ Sagimet Biosciences Inc - End-of-Phase 2 Meeting With U.S. Food and Drug Administration (FDA) Expected in Q2 of 2024

$Sagimet Biosciences (SGMT.US)$
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

$Sagimet Biosciences (SGMT.US)$ back to 20